Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23457595 | 1.00 | LMNA (0.40) | LMNASMN1; SMN2CYP2A6HAO1IDO1 | |
| SCHEMBL23457529 | 0.81 | HTR3A (0.35) | SMN1; SMN2CYP2A6ALDH1A1DYRK1A | |
| SCHEMBL29699567 | 0.81 | HTR3A (0.35) | SMN1; SMN2CYP2A6ALDH1A1DYRK1A | |
| SCHEMBL29699370 | 0.81 | HAO1 (0.53) | LMNASMN1; SMN2HAO1MAPTALDH1A1 | |
| SCHEMBL23457507 | 0.79 | HAO1 (0.43) | LMNASMN1; SMN2HAO1MAPTALDH1A1 | |
| SCHEMBL29699408 | 0.78 | NOTUM (0.43) | HAO1RHEB | |
| SCHEMBL23457559 | 0.77 | MARS1 (0.42) | LMNASMN1; SMN2MAPTALDH1A1ATM | |
| SCHEMBL23457570 | 0.77 | ALDH1A1 (0.38) | LMNASMN1; SMN2HAO1RHEBALDH1A1 | |
| SCHEMBL23458008 | 0.73 | AHR (0.42) | LMNASMN1; SMN2HAO1MAPTALDH1A1 | |
| SCHEMBL29699607 | 0.73 | AHR (0.42) | LMNASMN1; SMN2HAO1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | LMNA 2434/4885SMN1; SMN2 2118/4885CYP2A6 672/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | LMNA 2638/4885SMN1; SMN2 2010/4885CYP2A6 685/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | LMNA 2434/4885SMN1; SMN2 2118/4885CYP2A6 672/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | LMNA 2434/4885SMN1; SMN2 2118/4885CYP2A6 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.